TREATMENT PARADIGM FOR AN ANTI-CD19 ANTIBODY AND VENETOCLAX COMBINATION TREATMENT

Abstract: the present disclosure provides anti-cd19 antibodies and venetoclax for use in the treatment of non-hodgkin's lymphoma, chronic lymphocytic leukemia and/or small lymphocytic lymphoma. the anti-cd19 antibodies, in particular mor00208, and venetoclax are administered to patients suffering non-hodgkin's lymphoma (nhl), chronic lymphocytic leukemia (cll) and/or small lymphocytic lymphoma (sll) according to a specific treatment paradigm to mitigate therapy associated tumor lysis syndrome.

Inventor(s): Peter Kelemen, Michael Schwarz, Mark Winderlich, Steffen Heeger, Dominika Weinelt

CPC Classification: A61K31/573 (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms ; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles ; soap compositions ))

Search for rejections for patent application number 20250186460